Status:
COMPLETED
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
Lead Sponsor:
University of Saskatchewan
Conditions:
Breast Cancer
Premenopausal Breast Cancer
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with m...
Detailed Description
Recent evidence suggest that ovarian suppression in combination with exemestane compared with tamoxifen alone has been associated with significant reduction in risk of breast cancer recurrence in prem...
Eligibility Criteria
Inclusion
- • Premenopausal women with histologically-proven, completely resected, hormone receptor-positive (defined as ER≥10% and/or PgR≥10%) stage 1, 2, and 3 invasive breast cancer who are treated with combination of anti-estrogen therapy (LHRH agonist and an aromatase inhibitor or tamoxifen)
Exclusion
- Post-menopausal women
- Women who are on single agent endocrine therapy
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2024
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT03407768
Start Date
July 1 2018
End Date
November 30 2024
Last Update
December 5 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Allan Blair Cancer Center
Regina, Saskatchewan, Canada
2
Saskatoon Cancer Center
Saskatoon, Saskatchewan, Canada, S7N4H4